Sofinnova Partners launches a €300M biotech startup fund with a transatlantic focus

John Carroll

PARIS has reloaded its cash reserves and started to build the next wave of 15 to 20 biotechs for its portfolio. The venture group has wrapped a €300 million ($ 324 million) , easily blazing past its €250 million goal and far surpassing any of the earlier 7 funds that preceded it. Sofinnova Capital VIII brings the total amount under its management to €1.5 billion.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS